Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences develops FASN inhibitor drugs, led by denifanstat, for liver disease, acne and certain cancers. It last closed at $9.85 on Nov 17, down 2.76% on the day. The average 12-month price target from 8 analysts is $25.71 (+161.1% from the last close), with a high of $50.00 and a low of $7.00. Analyst consensus is Buy, based on the latest ratings from 8 firms (7 buy, 0 hold, 1 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in SGMT, 100% of them bullish and 0% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From SGMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on SGMT in the past 90 days. The average target is $25.71, with a high of $50.00 and a low of $7.00, compared with the last close of $9.85.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Canaccord Genuity | Target lowered | Buy | $56 → $50 |
| Oct 2 | Guggenheim | Maintained | Buy | $26 |
| Oct 1 | Oppenheimer | Maintained | Buy | $38 |
| Oct 1 | Citizens | Target lowered | Buy | $29 → $27 |
| Sep 24 | Goldman Sachs | Reinstated | Sell | $7 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 21% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $9.60, and the nearest resistance the Pivot at $9.89.
| RSI (14) | 48.56 | Middle of its range | Neutral |
| MACD | 0.22 | Below its signal line | Bearish |
| Stochastic | 43.3 | Middle of its range | Neutral |
| ADX (14) | 19.2 | No clear trend | |
| Williams %R | -65.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -44.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.66 | Typical daily range, 6.7% of price |
| RSI (14) | 56.93 | Middle of its range | Neutral |
| MACD | 0.66 | Below its signal line | Bearish |
| Stochastic | 65.3 | Middle of its range | Neutral |
| ADX (14) | 28.4 | Trending up | |
| Williams %R | -40.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 37.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −9.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.33 | Typical daily range, 13.5% of price |
What happened before
See how SGMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SGMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in SGMT in the last 90 days.
SGMT Institutional Ownership
Full report →- ▲107 buying vs 43 selling
- ▲Shares held by funds +36.7%
- ▲Funds holding +32
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 154 | 122 | +26.2% |
| In funds' top 10 | 3 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 50 / 57 | 57 / 37 | +13.8% |
| Reduced / sold out | 23 / 20 | 9 / 24 | +30.3% |
| Put/call ratio | 11.31 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGMT is in one of them and how their past SGMT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SGMT in an article yet. Here's the latest on the wider market.
About Sagimet Biosciences
Sagimet Biosciences is a biopharmaceutical company based in Foster City, California, that develops drugs called FASN inhibitors. Its lead candidate, denifanstat, is a pill taken by mouth once a day that is being studied for MASH, a serious form of fatty liver disease, along with acne and certain cancers. A second candidate, TVB-3567, is in early human testing for acne. The company aims these medicines at patients with metabolic and liver conditions, and a licensee in China is developing denifanstat for acne.
- Headquarters
- Foster City, CA



